| Belatacept - Wikipedia, the free encyclopedia Belatacept (trade name Nulojix) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is ... Read More |
| NULOJIX® (belatacept) - Official Site Nulojix® (belatacept) official Web site for healthcare professionals. Read More |
| FDA Approves Belatacept for Kidney Transplant Patients Belatacept is approved for use with corticosteroids and the immunosuppressant agents basiliximab and mycophenolate mofetil. This novel biologic agent is a fusion ... Read More |
| FDA Advisory Committee Recommends Approval of Belatacept, an ... Belatacept is a new drug in development to prevent graft rejection and maintain kidney function following renal transplantation.. Belatacept information includes news ... Read More |
| Belatacept: Abstract and Introduction In the past decade, the availability of new immunosuppressive maintenance therapies for use in solid organ transplantation has remained limited. Patients ... Read More |
| Belatacept (BMS-224818) FDA’s Cardiovascular and Renal Drugs ... TITLE PAGE Belatacept (BMS-224818) FDA’s Cardiovascular and Renal Drugs Advisory Committee Briefing Document for March 2010 Meeting BLA 125288 Read More |
| FDA Approves Transplant Drug That Preserves Kidneys, Avoids ... The Food and Drug Administration (FDA) has approved the drug Nulojix (belatacept) for the prevention of graft rejection after kidney transplants. Read More |
| New Data from Bristol-Myers Squibb on NULOJIX® (belatacept) to be ... PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that new data on NULOJIX (belatacept) will be presented at the European ... Read More |
| Belatacept-based regimens are associated with improved ... 1. Transplantation. 2011 May 15;91(9):976-83. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with ... Read More |
| Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS) Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS) Increased Risk of Post-transplant Lymphoproliferative Disorder (PTLD), predominantly involving ... Read More |
